← Back to Search

Virus Therapy

Gene Therapy + Chemoradiotherapy for Glioblastoma

Phase 1 & 2
Recruiting
Led By David S Baskin, MD
Research Sponsored by David Baskin MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have biopsy proven recurrent anaplastic astrocytoma or glioblastoma multiforme without evidence of multifocal tumor or brainstem involvement
Patients should have the following characteristics: recurrent glioblastoma or AA demonstrated by biopsy or imaging study, ECOG performance status of 0-1, has had prior surgery and radiotherapy/chemotherapy for the glioblastoma
Must not have
Presence of active or suspected acute or chronic uncontrolled infection or history of immunocompromise, including a positive HIV test result
Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications (Valacyclovir)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 60 months as measured in months
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying if a combination of HSV-tk gene therapy, valacyclovir, radiotherapy, and temozolomide is effective in treating patients with glioblastoma multiforme that has come back.

Who is the study for?
This trial is for adults with recurrent anaplastic astrocytoma or glioblastoma multiforme, confirmed by biopsy. Participants must have a life expectancy of at least 12 weeks, be recovered from previous treatments, and not have multifocal disease or brainstem involvement. They should use effective birth control and agree to provide biopsies. Those with other active cancers (except certain skin cancers), pregnant or breastfeeding women, and individuals unable to take oral medications are excluded.
What is being tested?
The study tests the combination of HSV-tk gene therapy with valacyclovir medication, stereotactic body radiotherapy (SBRT), and chemotherapy in patients who have had their glioblastoma return. It aims to evaluate the safety and effectiveness of this approach.
What are the potential side effects?
Potential side effects may include reactions related to gene therapy such as flu-like symptoms, issues from valacyclovir like headache or nausea, complications from radiotherapy including fatigue or skin irritation, and typical chemotherapy side effects like hair loss, nausea/vomiting, low blood counts leading to increased infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a confirmed diagnosis of recurrent anaplastic astrocytoma or glioblastoma without multiple tumor locations or brainstem involvement.
Select...
I have recurrent glioblastoma, can mostly care for myself, and had surgery and treatment before.
Select...
I am not pregnant or breastfeeding and have a recent negative pregnancy test.
Select...
I am using effective birth control methods.
Select...
My recent blood tests show my organs are functioning well.
Select...
I have no active cancer except for skin cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have an active infection or a compromised immune system.
Select...
I cannot swallow pills due to a condition in my upper GI tract.
Select...
I am under 18 years old.
Select...
I have an active brain infection shown on brain scans.
Select...
My cancer has spread to multiple areas including the brainstem.
Select...
I am taking immunosuppressive drugs, not including steroids for brain swelling.
Select...
My cancer has not spread widely in my brain or spine.
Select...
I have liver disease, like cirrhosis or hepatitis B/C.
Select...
I am not allergic to the medications used in this study.
Select...
I haven't had immunotherapy or gene therapy in the last 3 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 60 months as measured in months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 months as measured in months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Survival in months from Study drug administration (Day 0)
Secondary study objectives
Progression Free Survival assessments will be done every 6-8 weeks for 1st year thereafter every 12-14 weeks until disease progression or death

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ADV/HSV-tk (gene therapy)Experimental Treatment1 Intervention
The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 10 sessions (over 2 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent or after completion of the radiotherapy dependent on patient status based on best clinical judgment. Patient can receive second treatment of HSV-tk after 6 months

Find a Location

Who is running the clinical trial?

Center for Cell and Gene Therapy, Baylor College of MedicineOTHER
112 Previous Clinical Trials
2,793 Total Patients Enrolled
2 Trials studying Glioblastoma
18 Patients Enrolled for Glioblastoma
David Baskin MDLead Sponsor
David S Baskin, MDPrincipal InvestigatorHouston Methodist Neurological Institute

Media Library

ADV/HSV-tk (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03596086 — Phase 1 & 2
Glioblastoma Research Study Groups: ADV/HSV-tk (gene therapy)
Glioblastoma Clinical Trial 2023: ADV/HSV-tk Highlights & Side Effects. Trial Name: NCT03596086 — Phase 1 & 2
ADV/HSV-tk (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03596086 — Phase 1 & 2
~8 spots leftby Nov 2025